Complications Following Cervical Laminoplasty With Reconstruction: A Systematic Review and Meta-Analysis.

Spine (Phila Pa 1976)May 25, 2026 (epub)
Clinical ResearchNeurosurgeryOrthopedic Surgery

Charu Jain, Jennifer Yu, Jonathan J Huang et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated complication rates following cervical laminoplasty with reconstruction in 6732 patients. The study found a pooled incidence of C5 palsy at 4.07%, with higher rates in patients with ossification of the posterior longitudinal ligament (OPLL) compared to those with degenerative cervical myelopathy (DCM).

Key findings

  • C5 palsy occurred in 4.07% of patients, significantly higher in OPLL (5.86%) than DCM (3.34%).
  • Axial neck pain was reported in 13.74% of patients, the most common complication.
  • Reoperation rates were 2.72%, with dural/CSF complications at 1.48%.

Why it matters

Understanding the complication rates associated with cervical laminoplasty is crucial for clinicians to inform patients about potential risks and to guide surgical decision-making. Standardized definitions of complications could enhance future research and patient care.

Source

PubMed · PMID 42202771

Published in Spine (Phila Pa 1976). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurosurgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.